The Battle Of Blockbuster Heart Drugs

About to be an also-ran, Bristol gambles on a costly study--and wins

Confused by competing claims for the newest of the cholesterol-lowering drugs? You're not alone. Bristol-Myers Squibb Co.'s pravastatin, sold as Pravachol, and Merck & Co.'s simvastatin, or Zocor, offer a revolutionary approach to combating heart disease, the nation's No.1 killer. They are locked in a fierce battle over a market estimated at $6.5 billion.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.